NCT06528496RecruitingPhase 2
N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
N10: Reduced Therapy for High-Risk Neuroblastoma
Source: ClinicalTrials.gov · Last updated 28 Aug 2026
Brief summary (registry, in English)
The purpose of this study is to find out whether N10 chemotherapy is a safe and effective treatment for children with high-risk neuroblastoma.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 45 (estimated)
- First submitted
- 22 Jul 2024
- Start date
- 22 Jul 2024
- Primary completion date
- 22 Jul 2029
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Diseases
- Neuroblastoma, Childhood cancers
- NCT number
- NCT06528496
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 45
- From 22 Jul 2024 to the primary completion date, 22 Jul 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Severe dysfunction of major organs, i.e., renal, cardiac, hepatic, neurologic, pulmonary, hematologic, or gastrointestinal toxicity \>/= to grade 3
- °Organ dysfunction due to direct effects of primary tumor or metastatic disease, or due to paraneoplastic syndromes associated with neuroblastoma, will not be considered in exclusion criteria. Similarly, complications of interventions to control above direct effects (e.g., steroid- induced hyperglycemia or hypertension) will also not be considered in exclusion criteria
Other
- Inability to comply with protocol requirements
- Pregnancy
Who the study is looking for
- Diagnosis of NB as defined by histopathology, BM metastases plus high urine catecholamine levels, or positivity in MIBG scan.
- HR-NB, defined as MYCN-amplified stage L2/M/MS at any age and stage M in patients \>18 months old.
- No more than one prior cycle of HR-NB chemotherapy
- Age \<19 years.
- Signed informed consent indicating awareness of the investigational nature of this treatment.
Age in the registry: 18 months to 19 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Memorial Sloan-Kettering Cancer Center Coordinator of this site? Confirm its status | New York | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.